![Michael Gray](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 199 261 $ al 30/06/2026
Michael Paul Gray currently works at The American Institute of Certified Public Accountants, as Member and Upstream Bio, Inc., as Chief Financial & Operating Officer from 2024.
Mr. Gray also formerly worked at X4 Pharmaceuticals, Inc., as President, Chief Executive Officer & CFO from 2018 to 2019, Arsanis, Inc., as President, CEO, Chief Financial Officer & Director from 2018 to 2022, Therapeutics Acquisition Corp., as Independent Director from 2020 to 2021, Curis, Inc., as Secretary, Chief Financial & Business Officer from 2014 to 2016, Tetraphase Pharmaceuticals, Inc., as Chief Financial Officer & Senior Vice President, Reprogenesis, Inc., as Controller from 1998 to 2000, Enliven Therapeutics, Inc., as Chief Financial & Operating Officer from 2019 to 2023, Carmot Therapeutics, Inc., as Chief Operating & Financial Officer from 2023 to 2024, and Imara, Inc., as Chief Financial & Operating Officer from 2019 to 2023.
Mr. Gray received his undergraduate degree from Bryant University and Masters Business Admin degree from F.W.
Olin Graduate School of Business.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
UPSTREAM BIO, INC. 0,05 % | 16/06/2026 | 28.795 ( 0,05 % ) | 199 261 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| UPSTREAM BIO, INC. | Director Financiero/CFO | 01/03/2024 |
The American Institute of Certified Public Accountants
 The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Association of accountants | Corporate Officer/Principal | - |
| Empresas | Cargo | Fin |
|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Director Financiero/CFO | 01/02/2024 |
| IMARA | Director Financiero/CFO | 01/03/2023 |
| ENLIVEN THERAPEUTICS, INC. | Director Financiero/CFO | 23/02/2023 |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Director Ejecutivo | 01/03/2022 |
| THES ACQU | Director/Miembro de la Junta | 01/07/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 13 |
|---|---|
Curis, Inc.
 Curis, Inc. BiotechnologyHealth Technology Develops therapeutics to treat cancer | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Arsanis, Inc.
Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
The American Institute of Certified Public Accountants
The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Association of accountants | Commercial Services |
Reprogenesis, Inc.
 Reprogenesis, Inc. BiotechnologyHealth Technology Produces products in urology, cardiovascular biology, plastic, and reconstructive surgery | Health Technology |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Health Technology |
F.W. Olin Graduate School of Business
 F.W. Olin Graduate School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes novel therapeutics for patients with sickle cell disease | Health Technology |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Upstream Bio, Inc.
 Upstream Bio, Inc. BiotechnologyHealth Technology Engages in developing treatments for inflammatory diseases | Health Technology |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
